In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...